GlassScriptPhysician profile
Ted R Vaughn
NPI 1184757288
$635.37
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $66.56 · 2021: $305 · 2022: $17.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $137.58 | 2019-2021 | |
| Organogenesis INC. | $126.03 | 2019-2022 | |
| Mentor Worldwide LLC | $122.29 | 2021 | |
| Smith+Nephew, INC. | $44.44 | 2019-2020 | |
| Allergan, INC. | $31.47 | 2019-2021 | |
| Kci USA, INC. | $30.10 | 2021 | |
| Merz North America, INC. | $29.43 | 2019 | |
| Avanos Medical | $17.60 | 2021 | |
| Amgen INC. | $16.41 | 2021 | |
| Osiris Therapeutics INC. | $16.01 | 2019 | |
| Davol INC. | $13.33 | 2021 | |
| Galderma Laboratories, L.P. | $13.05 | 2019 | |
| Medtronic USA, INC. | $12.85 | 2020 | |
| Medela LLC | $12.73 | 2021 | |
| Stryker Corporation | $12.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.